Human CD274/PD-L1/B7-H1 protein (Recombinant) (N-His) (STJP006109)
SPECIFICATIONS
HostE.coli
ImmunogenHomo sapiens (Human)
General Information
| Short Description | Recombinant-Human CD274/PD-L1/B7-H1-N-His protein was developed from e.coli for the region N-His. For use in research applications. |
| Applications | ELISA/Immunogen/SDS-PAGE/WB |
| Host | E.coli |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Dilution Range | Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details. |
| Formulation | Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol. |
| Storage Instruction | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at-20 to-80°C for twelve months from the date of receipt. |
Target Information
| Gene Symbol | CD274 |
| Gene ID | 29126 |
| Uniprot ID | PD1L1_HUMAN |
| Immunogen | Homo sapiens (Human) |
| Immunogen Region | Phe19-Arg238 |
Additional Info
| Post Translational Modifications | Ubiquitinated.STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. Ubiquitinated by MARCHF8.leading to degradation. Deubiquitinated by USP22.leading to stabilization. |
| Function | Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival. The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function. The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. |
| Protein Name | Programmed Cell Death 1 Ligand 1Pd-L1Pdcd1 Ligand 1Programmed Death Ligand 1Hpd-L1B7 Homolog 1B7-H1Cd Antigen Cd274 |
| Database Links | Reactome: R-HSA-389948Reactome: R-HSA-9701898 |
| Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinEarly Endosome MembraneRecycling Endosome MembraneNucleusAssociates With Cmtm6 At Recycling EndosomesWhere It Is Protected From Being Targeted For Lysosomal DegradationTranslocates To The Nucleus In Response To Hypoxia Via Its Interaction With Phosphorylated Stat3Isoform 1: Cell MembraneIsoform 2: Endomembrane SystemIsoform 4: Secreted |
| Alternative Protein Names | Programmed Cell Death 1 Ligand 1 proteinPd-L1 proteinPdcd1 Ligand 1 proteinProgrammed Death Ligand 1 proteinHpd-L1 proteinB7 Homolog 1 proteinB7-H1 proteinCd Antigen Cd274 proteinCD274 proteinB7H1 proteinPDCD1L1 proteinPDCD1LG1 proteinPDL1 protein |
Information sourced from Uniprot.org